Correction: Oxidative stress induced inflammation initiates functional decline of tear production

Features of the clinical picture of keratitis in horses with different forms of the course of the disease

Background

Keratitis is a common cause of eye diseases in horses, often resulting in complete loss of vision.

Aim

The purpose of this article is to study the features of the clinical picture of primary and secondary keratitis in horses, depending on the form of the course of the disease.

Methods

The study was conducted in 2019 at 22 private horse breeding farms. The study involved 80 horses with keratitis, which were divided into two equal groups depending on the diagnosis of primary or secondary keratitis.

Results

The effectiveness of the therapies was compared 1, 3, and 6 months after the start of treatment. Following a 1-month therapy, only a minority of horses with primary keratitis had their eye functions fully restored, the number of horses with macula was two times higher (p ≤ 0.05), the number of horses with nebula was seven times higher (p ≤ 0.001), and leukomas were reported in most of the cases ( p ≤ 0.0001).

Conclusion

The effectiveness of the therapy for keratitis is directly related to the peculiarities of treatment and adherence to the regimen.

Exploring the Protective Potential of Carboxymethyl Terminalia catappa Polysaccharide on Blue Light Light-Emitting Diode Induced Corneal Damage

BACKGROUND

Excessive blue light light-emitting diode (LED) exposure and consequent oxidative stress causes corneal damage and corneal injuries are the major problem arising these days due to excessive use of mobile phone, TV, environment pollution, etc. Objective: In the present investigation, the protectiveness of carboxymethyl Terminalia catappa (CTC) from blue light LED-induced corneal damage was explored.

METHODS

For this purpose, Terminalia catappa (TC) was functionalized by carboxymethylation and its structural modification was confirmed by spectral attributes. Further, the CTC protective eye drop formulations (0.025-1%, w/v) were prepared and evaluated for their capability of protection from blue light LEDinduced corneal damage as compared to CTC protective eye gel (1.25-7%, w/v). The findings pointed towards excellent protection of CTC gel formulations as compared to CTC eye drop formulations. In addition, the prepared optimized CTC gel had thixotropic behavior as evident from percentage structural recovery which was 1.75 fold higher than marketed formulation (I-Comfort, HPMC 2%, w/v). The safety and non-toxicity of CTC protective eye drop and gel were confirmed by HET-CAM test. Further, a rat eye model was implemented that mimic blue light light-emitting diode induced corneal damage in day to day life to assess the protective effect of CTC protective eye drop and gel.

RESULTS

The order of protectiveness of CTC formulations was found to be CTC protective eye gel (4%, w/v) (no corneal damage)>marketed eye gel (12.34% corneal damage)=CTC protective eye drop (0.75%, w/v) (17.48% corneal damage)> marketed eye drop (51% corneal damage). The mechanism behind the protective effect of CTC eye drop and gel was associated with good free radical scavenging activity and corneal adhesive property of CTC. It is established from the present work that, carboxymethyl Terminalia catappa has protective action against blue light light-emitting diode induced corneal damage.

Clinical Evaluation of a Royal Jelly Supplementation for the Restoration of Dry Eye: A Prospective Randomized Double Blind Placebo Controlled Study and an Experimental Mouse Model

Background

Dry eye is a multifactorial disease characterized by ocular discomfort and visual impairment. Lacrimal gland function has been shown to decrease with aging, a known potent risk factor for dry eye. We have previously found that orally administrated royal jelly (RJ) restored tear secretion in a rat model of dry eye.

Methods and Findings

We examined the effects of RJ oral administration on dry eye in this prospective, randomized, double-blind, placebo-controlled study. Forty-three Japanese patients aged 20–60 years with subjective dry eye symptoms were randomized to an RJ group (1200 mg/tablet, six tablets daily) or a placebo group for 8 weeks. Keratoconjunctival epithelial damage, tear film break-up time, tear secretion volume, meibum grade, biochemical data, and subjective dry eye symptoms based on a questionnaire were investigated at baseline, and at 4 and 8 weeks after intervention. Adverse events were reported via medical interviews. In the RJ group, tear volume significantly increased after intervention (p = 0.0009). In particular, patients with a baseline Schirmer value of ≤10 mm showed a significant increase compared with baseline volume (p = 0.0005) and volume in the placebo group (p = 0.0051). No adverse events were reported. We also investigated the effect of RJ (300 mg/kg per day) administration using a mouse model of dry eye. Orally repeated administration of RJ preserved tear secretion, potentially through direct activation of the secretory function of the lacrimal glands.

Conclusion

Our results suggest that RJ improves tear volume in patients with dry eye.

Trial Registration

Registered NO. the University Hospital Medical Information Network in Japan (UMIN000014446)